CoChat

Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments

Open access
Cauwels, Anje, Van Lint, Sandra, Paul, Franciane, Garcin, Geneviève, De Koker, Stefaan, Van Parys, Alexander, Wueest, Thomas, Gerlo, Sarah, Van der Heyden, José, Bordat, Yann, Catteeuw, Dominiek, Rogge, Elke, Verhee, Annick, Vandekerckhove, Bart, Kley, Niko, Uzé, Gilles, Tavernier, Jan · 2018 · Cancer Research
Cited by 97

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

An ideal generic cancer immunotherapy should mobilize the immune system to destroy tumor cells without harming healthy cells and remain active in case of recurrence. Furthermore, it should preferably not rely on tumor-specific surface markers, as these are only available in a limited set of malignancies. Despite approval for treatment of various cancers, clinical application of cytokines is still impeded by their multiple toxic side effects. Type I IFN has a long history in the treatment of cancer, but its multifaceted activity pattern and complex side effects prevent its clinical use. Here we develop AcTakines (Activity-on-Target cytokines), optimized (mutated) immunocytokines that are up to 1,000-fold more potent on target cells, allowing specific signaling in selected cell types only. Type I IFN-derived AcTaferon (AFN)-targeting Clec9A+ dendritic cells (DC) displayed strong antitumor activity in murine melanoma, breast carcinoma, and lymphoma models and against human lymphoma in humanized mice without any detectable toxic side effects. Combined with immune checkpoint blockade, chemotherapy, or low-dose TNF, complete tumor regression and long-lasting tumor immunity were observed, still without adverse effects. Our findings indicate that DC-targeted AFNs provide a novel class of highly efficient, safe, and broad-spectrum off-the-shelf cancer immunotherapeutics with no need for a tumor marker. Significance: Targeted type I interferon elicits powerful antitumor efficacy, similar to wild-type IFN, but without any toxic side effects. Cancer Res; 78(2); 463–74. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-17-1980

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 97

Metadata

Authors
Cauwels, A., Van Lint, S., Paul, F., Garcin, G., De Koker, S., Van Parys, A., Wueest, T., Gerlo, S., Van der Heyden, J., Bordat, Y., Catteeuw, D., Rogge, E., Verhee, A., Vandekerckhove, B., Kley, N., Uzé, G., & Tavernier, J.
Venue
Cancer Research
Published
2018-01-15
Volume
78
Issue
2
Pages
463-474
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2770901637
Cited by
97
References
14
FWCI
3.35
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-1980
The paper
Cauwels, A., Van Lint, S., Paul, F., Garcin, G., De Koker, S., Van Parys, A., Wueest, T., Gerlo, S., Van der Heyden, J., Bordat, Y., Catteeuw, D., Rogge, E., Verhee, A., Vandekerckhove, B., Kley, N., Uzé, G., & Tavernier, J. (2018). Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-1980

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.